Prasinezumab slows motor progression in rapidly progressing early-stage Parkinson’s disease

Although in the PASADENA phase 2 study, the primary endpoint sum of Parts I + II + III) was not met, prasinezumab-treated individuals exhibited slower progression of motor signs than placebo-treated participants . We report here an exploratory analysis assessing whether prasinezumab showed greater benefits on motor signs progression in prespecified subgroups with faster motor progression.

The study is sponsored by F. Hoffmann-La Roche Ltd. F. Hoffmann-La Roche Ltd was involved in the study design, collection, analysis, interpretation of data, the writing of this article and the decision to submit it for publication. We thank the patients and their families who participated in the study and the clinical investigators.

Car Car Latest News, Car Car Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Parkinson's drug may be first that slows the condition's progressionMonthly infusions with the drug prasinezumab appeared to slow the progression of motor symptoms in people with advanced Parkinson's disease
Source: newscientist - 🏆 541. / 51 Read more »

Parkinson's disease progression slowed by antibody infusionsMonthly infusions with the drug prasinezumab appeared to slow the progression of motor symptoms in people with advanced Parkinson's disease
Source: newscientist - 🏆 541. / 51 Read more »